StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury

StemCells, Inc. STEM, -3.17% a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI).